Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Business Wire
- Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million -- Restructuring Expenses of $32.8 million Recorded -- GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 -- Conference Call and Webcast Today at 5:00 PM Eastern Time - ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.“In the first quarter of 2024, Exelixis made important progress to advance a diverse, multi-product portfolio of small molecules and biotherapeutics with the potential to improve standards of care for patients with cancer,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “The team continued to execute across our three ongoing pivotal trials for zanzalintinib, as well as the phase 1 stu
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Stephens. They set an "equal weight" rating and a $23.00 price target on the stock.MarketBeat
- Exelixis files patent suit against India's Cipla over Cabometyx generics [Seeking Alpha]Seeking Alpha
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in MayBusiness Wire
- Exelixis (EXEL) International Revenue Performance Explored [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 4/30/24 - Miss
EXEL
Sec Filings
- 5/13/24 - Form 144
- 5/10/24 - Form 8-K
- 5/8/24 - Form SC
- EXEL's page on the SEC website